We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Studies
Mdf5.0
Modafinil Research
Mostly mechanism / observational
40 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Modafinil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 271 participants.
Based on 40 studies · 11 meta-analyses · 17 RCTs · 3,883 total participants
Confidence
High confidence
By outcome
Cognition & executive function
Mostly mechanism / observational15 studies
Sleepiness & sleep disorders
Mostly mechanism / observational13 studies
Safety profile
Mostly mechanism / observational5 studies
Focus & attentionSignificantly improves objective wakefulness in narcolepsy, shift-work disorder, and treated OSA; in healthy adults, modest task-dependent cognitive benefit most consistent under demanding/sleep-deprived conditions · Hours per dose; weeks for steady benefit
Mostly mechanism / observational3 studies
Active research area
19 studies in the last 5 years · Latest meta-analysis: 2026
In plain English: Funding National Institute for Health and Care Research (NIHR303122).
Nourredine M, Jurek L, Hamza T, Cipriani A, Subtil F, Parlatini V, Farhat LC, Veronesi GF, Efthimiou O, Salanti G, Cortese S. · The lancet. Psychiatry (2026)
The 68 RCTs on children and adolescents included 14 138 participants (9981 [70·6%] males and 4157 [29·4%] females) and the 45 RCTs on adults included 11 016 participants (5958 [54·0%] males and 5056 [46·0%] females).
We found no evidence of intransitivity.
Interpretation Our findings challenge both therapeutic inertia-accepting suboptimal response without further dose titration-and uncritical dose escalation beyond licensed limits, when potential harms outweigh expected benefits.